Amy K Saenger1, Olaia Rodriguez-Fraga2, Ranka Ler3, Jordi Ordonez-Llanos4, Allan S Jaffe5, Jens Peter Goetze6, Fred S Apple7,8. 1. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN. 2. Laboratory Medicine Department, Hospital Universitario La Paz, Madrid, Spain. 3. Minneapolis Medical Research Foundation, Minneapolis, MN. 4. IIB-Hospital de la Santa Creu i Sant Pau and Universitat Autònoma, Barcelona, Spain. 5. Department of Internal Medicine, Division of Cardiology, Mayo Clinic, Rochester, MN. 6. Rigshospitalet, University of Copenhagen, Denmark. 7. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN; apple004@umn.edu. 8. Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN.
Abstract
BACKGROUND: B-type natriuretic peptides (BNPs) are used clinically to diagnose and monitor heart failure and are present in the circulation as multiple proBNP-derived fragments. We investigated the specificity of BNP immunoassays with glycosylated and nonglycosylated BNP, N-terminal proBNP (NT-proBNP), and proBNP peptides to probe the cross-reactivity of each assay. METHODS: Nine B-type natriuretic peptides were studied,including synthetic and recombinant BNP (Shionogi, Scios, Mayo), human and synthetic glycosylated and nonglycosylated NT-proBNP (HyTest, Roche Diagnostics), and human glycosylated and nonglycosylated proBNP (HyTest, Scios). Five BNP [Abbott, Abbott POC, Alere, Beckman Coulter, Siemens (Centaur)], 9 NT-proBNP [Ortho-Clinical Diagnostics, Roche, Response, bioMerieux, Siemens (Dimension, Immulite, Stratus CS), Mitsubishi] and 3 research-use-only proBNP immunoassays [Biosite (Alere), Bio-Rad, Goetze] were evaluated. Specificity was assessed by calculating the recovery between baseline and peptide-spiked human plasma pools at target concentrations of 100 ng/L BNP, 300 ng/L proBNP, or 450 ng/L NT-proBNP. All assays were performed in duplicate. RESULTS: BNP and NT-proBNP assays demonstrated substantial cross-reactivity with proBNP peptides. NT-proBNP assays do not detect glycosylated forms of either NT-proBNP or proBNP. proBNP assays preferentially detect the BNP 1-32 peptide and have minimal cross-reactivity with BNP peptides and glycosylated proBNP. CONCLUSIONS: BNP or NT-proBNP results are not transferable among the current existing immunoassays owing to their differences in cross-reactivity and ability to detect various glycosylated forms of proBNP-derived fragments. Opportunities remain to standardize and harmonize BNP and NT-proBNP assays, as well as to develop specific proBNP assays, to widen their clinical scope of use.
BACKGROUND: B-type natriuretic peptides (BNPs) are used clinically to diagnose and monitor heart failure and are present in the circulation as multiple proBNP-derived fragments. We investigated the specificity of BNP immunoassays with glycosylated and nonglycosylated BNP, N-terminal proBNP (NT-proBNP), and proBNP peptides to probe the cross-reactivity of each assay. METHODS: Nine B-type natriuretic peptides were studied,including synthetic and recombinant BNP (Shionogi, Scios, Mayo), human and synthetic glycosylated and nonglycosylated NT-proBNP (HyTest, Roche Diagnostics), and human glycosylated and nonglycosylated proBNP (HyTest, Scios). Five BNP [Abbott, Abbott POC, Alere, Beckman Coulter, Siemens (Centaur)], 9 NT-proBNP [Ortho-Clinical Diagnostics, Roche, Response, bioMerieux, Siemens (Dimension, Immulite, Stratus CS), Mitsubishi] and 3 research-use-only proBNP immunoassays [Biosite (Alere), Bio-Rad, Goetze] were evaluated. Specificity was assessed by calculating the recovery between baseline and peptide-spiked human plasma pools at target concentrations of 100 ng/L BNP, 300 ng/L proBNP, or 450 ng/L NT-proBNP. All assays were performed in duplicate. RESULTS:BNP and NT-proBNP assays demonstrated substantial cross-reactivity with proBNP peptides. NT-proBNP assays do not detect glycosylated forms of either NT-proBNP or proBNP. proBNP assays preferentially detect the BNP 1-32 peptide and have minimal cross-reactivity with BNP peptides and glycosylated proBNP. CONCLUSIONS:BNP or NT-proBNP results are not transferable among the current existing immunoassays owing to their differences in cross-reactivity and ability to detect various glycosylated forms of proBNP-derived fragments. Opportunities remain to standardize and harmonize BNP and NT-proBNP assays, as well as to develop specific proBNP assays, to widen their clinical scope of use.
Authors: Nicole E Pollok; Charlie Rabin; Charuksha T Walgama; Leilani Smith; Ian Richards; Richard M Crooks Journal: ACS Sens Date: 2020-03-10 Impact factor: 7.711
Authors: Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold Journal: Nat Rev Cardiol Date: 2020-05-22 Impact factor: 32.419
Authors: Chris J Watson; Nadezhda Glezeva; Stephen Horgan; Joe Gallagher; Dermot Phelan; Ken McDonald; Michael Tolan; John Baugh; Patrick Collier; Mark Ledwidge Journal: J Am Heart Assoc Date: 2020-05-20 Impact factor: 5.501
Authors: Erica M Dillon; Shouzuo D Wei; Deepak K Gupta; Hui Nian; Brooks S Rodibaugh; Katherine N Bachmann; Allen J Naftilan; Lynne W Stevenson; Nancy J Brown Journal: J Card Fail Date: 2021-06-13 Impact factor: 5.712